Aplastic Anemia Treatment Market Share

North American Market Forecast

The North American aplastic anemia treatment market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2036. The growth of the market is attributed to the availability of advanced treatment options for aplastic anemia, such as bone marrow transplantation, immunosuppressive therapy, and blood transfusions. In addition, the growing prevalence of deadly blood diseases such as leukemia, the rising awareness of the disease, and the increasing government funding for treatment are expected to drive regional market growth. The rising prevalence of blood disorders such as leukemia is primarily attributed to lifestyle changes, increasing exposure to environmental toxins, and genetic mutations. In 2021, the US experienced 186,400 new cases of leukemia, lymphoma, and myeloma. Based on the Leukemia & Lymphoma Society, approximately one person is diagnosed with leukemia, lymphoma, or myeloma every three minutes. Blood cancer was expected to account for about 10% of cancer diagnoses in Canada in 2019. Aplastic anemia treatment helps to treat leukemia by targeting the bone marrow, which is where leukemia originates. The treatment reduces the amount of abnormal white blood cells in the bone marrow, which helps to reduce the spread of cancer cells.

APAC Market Statistics

The Asia Pacific aplastic anemia treatment market, amongst the market in all the other regions, is projected to hold the second largest share during the forecast period. The growth of the market can be attributed to the increasing prevalence of aplastic anemia and the introduction of novel therapies such as hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST). Over the period from 2008 to 2019, 58,914 hematopoietic stem cell transplantations were reported by the Chinese Blood and Marrow Transplant Registry Group (CBMTRG). It is estimated that 12,323 HSCTs have been performed in 2019 from 149 transplant teams, of which 78% (9577) are allogeneic. Since the technology is more advanced and widely available in the region, stem cell donors are easier to find and HSCTs are more affordable. As a result, more patients are able to access HSCTs and HSCTs are being performed in Asia Pacific, resulting in a rise in the need for treatment of aplastic anemia. Additionally, the rising number of clinical trials and the growing focus on research and development of novel treatments are expected to drive the growth of the market in the Asia Pacific region.

Europe Market Forecast

Further, the aplastic anemia treatment market in the Europe, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2036. The growth of the market can be attributed the presence of advanced healthcare infrastructure and the availability of efficient and advanced treatment options such as stem-cell transplantation, chemotherapy and other treatments in the European region. Additionally, the rising awareness about the disease and the availability of government initiatives and healthcare subsidies to improve the access to treatments for the disease are expected to drive the growth of the market in the region. The increasing number of clinical trials that are being conducted in the region to develop new treatments and the growing number of collaborations between the government and the private entities to improve the access to better treatments are also expected to drive the growth of the market.